Investigational drug · Phase 3
Darovasertib
Also called: IDE 196, LXS196
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
6
Any phase or sponsor naming "Darovasertib"
First trial start
2019
Jun 28, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Darovasertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uveal Melanoma
- Metastatic Uveal Melanoma
- Cutaneous Melanoma
- Colorectal Cancer
- Other Solid Tumors
Approved drugs for the same conditions: Colorectal cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Darovasertib" as an intervention, largest first.
- Neoadjuvant Darovasertib in Primary Uveal MelanomaPivotal-lookingRecruiting
IDEAYA BiosciencesIndustry
NCT07015190 · 520 participants (planned) · Start Jan 25, 2026 · Primary completion Oct 2030
Drug: Darovasertib · For: Uveal Melanoma
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 94 sites in all
- Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaPivotal-lookingRecruiting
IDEAYA BiosciencesIndustry
NCT07804186 · 450 participants (planned) · Start Sep 4, 2026 · Primary completion Mar 2034
Drug: Darovasertib; Crizotinib (Xalkori) · For: Uveal Melanoma
Sites: Scottsdale, Arizona; Los Angeles, California; San Diego, California · 29 sites in all
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaPivotal-lookingActive, not recruiting
IDEAYA BiosciencesIndustry
NCT05987332 · 420 participants (planned) · Start Oct 31, 2023 · Primary completion Jan 15, 2027
Drug: IDE196; Crizotinib and 4 more · For: Metastatic Uveal Melanoma
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 68 sites in all
IDEAYA BiosciencesIndustry
NCT03947385 · 336 participants (planned) · Start Jun 28, 2019 · Primary completion Jan 29, 2027
Drug: IDE196; Binimetinib and 1 more · For: Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer and 1 more
Sites: Los Angeles, California; San Francisco, California; Denver, Colorado · 15 sites in all
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaActive, not recruiting
IDEAYA BiosciencesIndustry
NCT05907954 · 160 participants (planned) · Start Jul 3, 2023 · Primary completion Apr 30, 2027
Drug: Darovasertib · For: Uveal Melanoma
Sites: Scottsdale, Arizona; La Jolla, California; Palo Alto, California · 18 sites in all
St Vincent's Hospital, SydneyAcademic, hospital or other
NCT05187884 · 15 participants · Start May 3, 2022 · Primary completion Jan 1, 2025
Drug: Darovasertib · For: Ocular Melanoma
Sites: Sydney, Australia; Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study.
McKean M, Chmielowski B, Butler MO, et al. · J Clin Oncol 2026
- Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines.
Dalvin LA, Burr SD, Miley DR, et al. · Melanoma Res 2026
- Uveal Melanoma: Changing Paradigms of Treatment.
Piperno-Neumann S · Ocul Oncol Pathol 2026
- Adverse Events and Toxicity of Systemic Treatments for Uveal Melanoma: A Systematic Review.
Lanzafame K, Blanco G, Paratore S, et al. · Cancers (Basel) 2026
- Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma.
Lubrano S, Cervantes-Villagrana RD, Arang N, et al. · J Biol Chem 2025
- A Brief Overview of Uveal Melanoma Treatment Methods with a Focus on the Latest Advances.
Wdowiak K, Dolar-Szczasny J, Rejdak R, et al. · J Clin Med 2025
Also in development for Uveal Melanoma
- AU-011Bel-sarPhase 32 trials
Aura Biosciences · Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma
- APG-115Phase 24 trials
Ascentage Pharma Group Inc. · T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma, Liposarcoma
- roginolisibIOA-244Phase 23 trials
iOnctura · Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
- RBP-01Phase 21 trial
ReBio Pharma · Uveal Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.